Sermorelin and GLP-1 Medicines
Different drug classes, different purposes, and what is known about using both.
Sermorelin and GLP-1 medicines are different drug classes with different purposes. Sermorelin is a GHRH analog that signals the pituitary to release growth hormone. Semaglutide and tirzepatide are incretin-based medicines that act on GLP-1 receptors. No published human study has tested sermorelin together with a GLP-1 medicine. A licensed provider decides what fits.
Compounded sermorelin is not FDA-approved; sermorelin was approved as Geref in 1997 and discontinued in 2008.
Opens the Sermorelin application on OpenLoop, in English. Our care team can help in English or Spanish.
Why GLP-1 users ask about sermorelin
People on semaglutide or tirzepatide often search for what else they might add, and sermorelin shows up in those searches because it is also an injectable peptide. That overlap is about format, not purpose. The two act on different hormone systems, and neither is a substitute for the other.
Two drug classes, two purposes
- Sermorelin is a growth-hormone-releasing hormone (GHRH) analog. It signals the pituitary gland to release the body’s own growth hormone. Compounded sermorelin is not FDA-approved.
- Semaglutide is a GLP-1 receptor agonist. It mimics GLP-1, a gut hormone (an incretin): its label says it stimulates insulin release and lowers glucagon in a glucose-dependent way, and delays early stomach emptying after meals.
- Tirzepatide is also an incretin-based medicine prescribed for type 2 diabetes or chronic weight management.
- Different targets mean different purposes. Sermorelin is not a GLP-1 medicine and is not a weight-management treatment.
Is sermorelin like Ozempic?
No. Ozempic® contains semaglutide, a GLP-1 receptor agonist prescribed for type 2 diabetes. Sermorelin is a GHRH analog that signals the pituitary to release growth hormone. They belong to different drug classes, act on different receptors and serve different purposes. Sermorelin is not a GLP-1 medicine, and REMEVi does not prescribe it for weight management.
Ozempic® is a registered trademark of Novo Nordisk A/S. REMEVi is not affiliated with Novo Nordisk. Brand names appear for orientation.
Can you take sermorelin with semaglutide?
There is no published human research to answer that. A PubMed search on 2026-11-02 found no human study of sermorelin used together with semaglutide, tirzepatide or another GLP-1 medicine. That means safety and results of co-use are unstudied, not established. A licensed provider who knows your full medication list decides whether either medicine fits you.
What is studied is each medicine on its own: semaglutide in large trials described on its FDA label, and sermorelin in small growth-hormone studies from the 1990s.
Start with an evaluation
Opens the Sermorelin application on OpenLoop, in English. Our care team can help in English or Spanish.
Two programs, two evaluations
REMEVi offers both programs, and each has its own evaluation by a licensed provider. Being approved for one does not mean you are approved for the other, and the provider reviewing either request sees your full medication list.
- Sermorelin: $229 every 4 weeks (28 days), month-to-month.
- GLP-1 (semaglutide): Semaglutide from $159 / month on the 6-month plan — $169 / month on the 3-month plan, $199 / month, cancel any time. The same price at every dose, all-inclusive.
More questions
Does sermorelin help with weight?
Published studies do not show that. In the two small adult studies that measured body weight, it did not change over 6 or 16 weeks. REMEVi does not prescribe sermorelin for weight management; GLP-1 medicines are the program built for that goal.
Does sermorelin protect muscle while on a GLP-1?
That has not been studied. No published human study has tested sermorelin alongside a GLP-1 medicine, so there is no evidence either way. Ask your licensed provider about nutrition, protein and activity while on a GLP-1.
Should I tell my GLP-1 provider about sermorelin?
Yes. Tell every prescriber about every medicine, peptide and supplement you use, including anything bought online. That lets each licensed provider check your full picture before prescribing.
Opens the Sermorelin application on OpenLoop, in English. Our care team can help in English or Spanish.
Sources
- FDA prescribing information via DailyMed — OZEMPIC (semaglutide) injection (read November 2, 2026)
- PubMed search, title/abstract: sermorelin AND (semaglutide OR tirzepatide OR GLP-1 OR liraglutide) — no results (read November 2, 2026)
- Vittone et al., Metabolism 1997 — Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men (read November 2, 2026)
- Khorram et al., J Clin Endocrinol Metab 1997 — Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women (read November 2, 2026)
- Prakash & Goa, BioDrugs 1999 — Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency (read November 2, 2026)
- FDA — Orphan Drug Designations and Approvals: sermorelin acetate (Geref) (read November 2, 2026)
Medically reviewed by Linda West-Conforti, RN · CA RN #389453 ·